{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:06:26Z","timestamp":1790049986254,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01789-9","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T06:12:58Z","timestamp":1786169578000},"page":"4205-4216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence and Clinical Characteristics of Vitiligo-Associated Hearing Loss Among Patients in a Phase\u00a02 Clinical Trial of Povorcitinib"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04818346","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-2530","authenticated-orcid":false,"given":"Michael","family":"DePietro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9986-6047","authenticated-orcid":false,"given":"Leandro L.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8196-2181","authenticated-orcid":false,"given":"Zhenyi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8876-9777","authenticated-orcid":false,"given":"Kurt","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3492-0679","authenticated-orcid":false,"given":"Jason A.","family":"Brant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"10","key":"1789_CR1","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.18257","volume":"36","author":"K Bibeau","year":"2022","unstructured":"Bibeau K, Pandya A, Ezzedine K, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022;36(10):1831\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1789_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jaad.2020.12.029","volume":"85","author":"SH Ma","year":"2021","unstructured":"Ma SH, Ang MD, Chang YT, Dai YX. Association between vitiligo and hearing loss. J Am Acad Dermatol. 2021;85(6):1465\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1789_CR3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000350337","volume":"18","author":"E Fleissig","year":"2013","unstructured":"Fleissig E, Gross M, Ophir I, Elidan J, Bdolah-Abram T, Ingber A. Risk of sensorineural hearing loss in patients with vitiligo. Audiol Neurootol. 2013;18(4):240\u20136.","journal-title":"Audiol Neurootol"},{"issue":"1","key":"1789_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0896-6273(01)00259-8","volume":"30","author":"ER Price","year":"2001","unstructured":"Price ER, Fisher DE. Sensorineural deafness and pigmentation genes: melanocytes and the Mitf transcriptional network. Neuron. 2001;30(1):15\u20138.","journal-title":"Neuron"},{"issue":"1","key":"1789_CR5","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1038\/s41598-024-52629-9","volume":"14","author":"T Udagawa","year":"2024","unstructured":"Udagawa T, Takahashi E, Tatsumi N, et al. Loss of Pax3 causes reduction of melanocytes in the developing mouse cochlea. Sci Rep. 2024;14(1):2210.","journal-title":"Sci Rep"},{"issue":"7","key":"1789_CR6","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1111\/jdv.18047","volume":"36","author":"CL Li","year":"2022","unstructured":"Li CL, Ma SH, Wu CY, Chang PH, Chang YT, Wu CY. Association between sensorineural hearing loss and vitiligo: a nationwide population-based cohort study. J Eur Acad Dermatol Venereol. 2022;36(7):1097\u2013103.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1789_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5152\/iao.2023.22991","volume":"19","author":"X Li","year":"2023","unstructured":"Li X, Cao Z, Chen F, Yang D, Zhao F. Sensorineural hearing loss in autoimmune diseases: a systematic review and meta-analysis. J Int Adv Otol. 2023;19(4):277\u201382.","journal-title":"J Int Adv Otol"},{"key":"1789_CR8","doi-asserted-by":"publisher","first-page":"101830","DOI":"10.1016\/j.cegh.2024.101830","volume":"30","author":"S Tajik","year":"2024","unstructured":"Tajik S, Nazary K, Shirzadian Kebria A, Kiakojori K. Evaluation of auditory system in vitiligo patients: a case-control study. Clin Epidemiol Glob Health. 2024;30:101830.","journal-title":"Clin Epidemiol Glob Health"},{"issue":"2","key":"1789_CR9","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1055\/s-0039-1696700","volume":"24","author":"N Prabha","year":"2020","unstructured":"Prabha N, Arora R, Chhabra N, Jati M, Nagarkar NM. Audiological abnormalities in vitiligo patients: a hospital-based cross-sectional study. Int Arch Otorhinolaryngol. 2020;24(2):e149\u201353.","journal-title":"Int Arch Otorhinolaryngol"},{"issue":"4","key":"1789_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.17430\/JHS.2020.10.4.7","volume":"10","author":"AO Dabbous","year":"2020","unstructured":"Dabbous AO, Medhat MM, El-Mesidy MSE. Cochlear involvement in vitiligo patients. J Hear Sci. 2020;10(4):69\u201382.","journal-title":"J Hear Sci"},{"key":"1789_CR11","volume-title":"StatPearls [Internet]","author":"R Tanna","year":"2023","unstructured":"Tanna R, Lin J, De Jesus O. Sensorineural Hearing Loss. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2023."},{"issue":"1","key":"1789_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1365-2230.2005.02004.x","volume":"31","author":"K Aydogan","year":"2006","unstructured":"Aydogan K, Turan OF, Onart S, Karadogan SK, Tunali S. Audiological abnormalities in patients with vitiligo. Clin Exp Dermatol. 2006;31(1):110\u20133.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1789_CR13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jaad.2025.06.027","volume":"93","author":"AG Pandya","year":"2025","unstructured":"Pandya AG, Ezzedine K, Passeron T, et al. Efficacy and safety of the oral Janus kinase\u00a01 inhibitor povorcitinib in patients with extensive vitiligo in a phase\u00a02, randomized, double-blinded, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2025;93(4):946\u201355.","journal-title":"J Am Acad Dermatol"},{"key":"1789_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.18203\/issn.2454-5929.ijohns20160958","volume":"2","author":"A Maheshwari","year":"2016","unstructured":"Maheshwari A, Panigrahi R, Mahajan S. Vitiligo associated hypoacusis: a case control study. Int J Otorhinolaryngol Head Neck Surg. 2016;2:77.","journal-title":"Int J Otorhinolaryngol Head Neck Surg"},{"issue":"8","key":"1789_CR15","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/lary.29941","volume":"132","author":"E Kay-Rivest","year":"2022","unstructured":"Kay-Rivest E, Irace AL, Golub JS, Svirsky MA. Prevalence of single-sided deafness in the United States. Laryngoscope. 2022;132(8):1652\u20136.","journal-title":"Laryngoscope"},{"key":"1789_CR16","first-page":"100670","volume":"30","author":"DB Rein","year":"2024","unstructured":"Rein DB, Franco C, Reed NS, et al. The prevalence of bilateral hearing loss in the United States in 2019: a small area estimation modelling approach for obtaining national, state, and county level estimates by demographic subgroup. Lancet Reg Health. 2024;30:100670.","journal-title":"Lancet Reg Health"},{"key":"1789_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/pigmentinternational.pigmentinternational_71_21","volume":"10","author":"R Devi","year":"2023","unstructured":"Devi R, Rather S, Wani JS, Latoo M, Hassan I. Evaluation of auditory and ophthalmic abnormalities in adult vitiligo patients: a case-control study. Pigment Int. 2023;10:97\u2013104.","journal-title":"Pigment Int"},{"key":"1789_CR18","doi-asserted-by":"publisher","first-page":"867453","DOI":"10.3389\/fnins.2022.867453","volume":"16","author":"SS Liu","year":"2022","unstructured":"Liu SS, Yang R. Inner ear drug delivery for sensorineural hearing loss: current challenges and opportunities. Front Neurosci. 2022;16:867453.","journal-title":"Front Neurosci"},{"issue":"11","key":"1789_CR19","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/jdv.19450","volume":"37","author":"J Seneschal","year":"2023","unstructured":"Seneschal J, Speeckaert R, Taieb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force-part 2: specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023;37(11):2185\u201395.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1789_CR20","doi-asserted-by":"publisher","first-page":"102655","DOI":"10.1016\/j.eclinm.2024.102655","volume":"73","author":"T Passeron","year":"2024","unstructured":"Passeron T, Ezzedine K, Hamzavi I, et al. Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase\u00a02, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study. EClinicalMedicine. 2024;73:102655.","journal-title":"EClinicalMedicine"},{"issue":"2","key":"1789_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","volume":"88","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine K, Peeva E, Yamaguchi Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase\u00a02b clinical trial. J Am Acad Dermatol. 2023;88(2):395\u2013403.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01789-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01789-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01789-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:30:07Z","timestamp":1787243407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01789-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1789"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01789-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael DePietro, Leandro L. Santos, Zhenyi Xue, and Kurt Brown are employees and shareholders of Incyte. Jason A. Brant reports consultancy fees from Incyte.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the institutional review board or ethics committee at each participating site, including WCG (no. 20210846; Cary, NC, USA), the Research Review Board (no. 2021.562; Waterloo, ON, Canada), and the Biomedical Research Ethics Board, University of Manitoba (no. HS24854 [B2021:036]; Winnipeg, MB, Canada). The study was conducted in compliance with the Declaration of Helsinki, study protocol, applicable Good Clinical Practice, and all applicable laws and regulations. All patients provided written informed consent prior to any study procedures being undertaken.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}